Capstone Therapeutics Corp. — Form 10-Q Summary
Reporting period: Three and six months ended June 30, 2018; comparative periods ended June 30, 2017. The filing identifies the registrant as Capstone Therapeutics Corp., which differs from the request metadata naming Capstone Holding Corp. The statements are unaudited and consolidate the Company and its approximately 60%-owned subsidiary, LipimetiX Development, Inc.
Business Context
The Company is a biotechnology business focused primarily on developing AEM-28 and related Apo E mimetic peptides through LipimetiX. Prior product licenses for Chrysalin and AZX100 were terminated. Development activities remain limited because additional funding is required.
On May 2, 2018, LipimetiX granted Anji Pharmaceuticals Inc. a sublicense covering China, Taiwan and Hong Kong rights to AEM-28 and analogs. Anji is responsible for permitted development activities in the territory at its own cost.
Financial Performance and Position
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Sublicense revenue | $2.0 million in 2018; none in 2017 | $2.0 million in 2018; none in 2017 |
| Operating expenses | $660,000 vs. $214,000 | $1.190 million vs. $594,000 |
| Net income attributable to stockholders | $1.278 million vs. $(206,000) | $691,000 vs. $(593,000) |
| Basic and diluted earnings per share | $0.02 vs. $(0.01) | $0.01 vs. $(0.01) |
| Operating cash flow | $1.016 million in the first six months of 2018 vs. $(261,000) in 2017 |
The $2.0 million sublicense payment was recorded as revenue in the second quarter. Related transaction costs were $254,000, including payments to the University of Alabama at Birmingham Research Foundation, an advisory fee and legal fees. The resulting revenue was a significant nonrecurring contributor to reported profitability.
- Cash and cash equivalents: $2.291 million at June 30, 2018, compared with $1.275 million at December 31, 2017; $1.850 million was held by the joint venture.
- Total assets: $2.420 million, including $118,000 of net patent license rights.
- Current liabilities: $247,000.
- Secured debt and accrued interest: $2.355 million, compared with $2.249 million at December 31, 2017.
- Total stockholders’ equity: a deficit of $182,000, improved from a deficit of $879,000 at year-end 2017.
- Shares outstanding: 54.385 million as of June 30, 2018 and August 1, 2018.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $2.0 million due to the Anji sublicense.
- Six-month research and development expense increased to $623,000 from $379,000, while second-quarter expense increased to $322,000 from $112,000, reflecting greater funding availability following the 2017 investment in the joint venture.
- Six-month general and administrative expense increased to $313,000 from $215,000, primarily because of professional fees and timing of audit costs. Second-quarter G&A decreased to $84,000 from $102,000 following cost reductions, including reduced office space.
- Net interest and other expense increased to $122,000 for the first six months from $9,000, primarily due to secured-debt interest and warrant-related expense.
- Cash increased by $1.016 million during the first six months, entirely from operating activities; there were no investing or financing cash flows during the period.
Debt, Liquidity, Outlook and Risks
The Company has a $2.428 million secured loan from BP Peptides, LLC, bearing interest at 6% and due October 15, 2020. Interest payments were deferred to maturity under a January 2018 amendment. In exchange, the Company issued a warrant for up to 6.322 million shares at an exercise price of $0.075 per share; 1.463 million shares were vested and exercisable at June 30, 2018. BP Peptides owned approximately 34.1% of the Company’s common stock.
Management states that additional capital is required to continue operations and materially advance AEM-28 development. Potential funding sources include strategic or merger transactions, debt or equity offerings, partnering, licensing or joint-development arrangements. The Company intends to maintain a virtual operating model and limit development activities absent additional funding.
The joint venture’s losses exceeded its capital accounts at June 30, 2018. The Company had advanced $1.6 million under a revolving loan agreement; including accrued interest, the balance was $1.680 million, with the maturity extended to July 15, 2020, subject to early repayment provisions. If the joint venture cannot continue as a going concern, the Company could recognize an additional $667,000 of losses previously allocated to noncontrolling interests.
Key risks include insufficient funding, unfavorable clinical or preclinical results, regulatory delays or failure, competition, loss or impairment of intellectual property, dependence on collaborations and licensing transactions, the virtual operating model, possible OTCQB delisting and inability to implement the AEM-28 development strategy. No legal proceedings were reported, and management stated that no material loss contingency was reasonably possible, although outcomes of legal matters remain uncertain.
Investor Verification Checklist
- Verify the terms, revenue-recognition treatment and continuing obligations under the Anji sublicense, including royalties and milestone payments.
- Assess whether the $2.291 million cash balance, including cash held by the joint venture, is sufficient through the secured-loan maturity and for planned operations.
- Review the $2.355 million secured-debt balance, deferred interest, collateral provisions and October 15, 2020 maturity.
- Evaluate the potential dilution from the 6.322 million-share warrant and other joint-venture securities, options and warrants.
- Confirm the Company’s funding plan and the amount required to restart or expand AEM-28 clinical and development activities.
- Monitor the joint venture’s financial condition, the $1.680 million revolving-loan balance and the potential $667,000 additional loss exposure.
- Distinguish the one-time sublicense revenue from recurring operating performance when evaluating profitability and cash generation.